• Carnitine, gamma-trimethyl-beta-hydroxybutyrobetaine, is a small molecule widely present in all cells from prokaryotic to eukaryotic. It is an important element in the beta-oxidation of fatty acids. A lack of carnitine in hemodialysis patients is caused by insufficient carnitine synthesis and particularly by the loss through dialytic membranes, leading in some patients to carnitine depletion with a relative increase of esterified forms. The authors found a decrease in plasma-triglyceride and increase of high-density lipoprotein cholesterol (HDL-Chol) in dialysis patients during carnitine treatment. Many studies have shown that L-carnitine supplementation leads to improvements in several complications seen in uremic patients, including cardiac complications, impaired exercise and functional capacities, muscle symptoms, increased symptomatic intradialytic hypotension, and erythropoietinresistant anemia, normalizing the reduced carnitine palmitoyl transferase activity in red cells. In addition, carnitine supplementation may improve protein metabolism and insulin resistance. Recently, carnitine supplementation has been approved by the US Food and Drug Administration not only for the treatment, but also for the prevention of carnitine depletion in dialysis patients. Regular carnitine supplementation in hemodialysis patients can improve their lipid metabolism, protein nutrition, antioxidant status, and anemia requiring large doses of erythropoietin, It also may reduce the incidence of intradialytic muscle cramps, hypotension, asthenia, muscle weakness, and cardiomyopathy. Am J Kidney Dis 41(S1):S116-S122. © 2003 by the National Kidney Foundation, Inc.
ARNITINE (3-hydroxi-4-N-trimethylammoniobutanoate) is a short organic hydrosoluble molecule and is present in biological materials like free carnitine and acylcarnitines, which constitute the carnitine system together with the cellular proteins required for their metabolism and transport.
The history of carnitine dates from 1905, when Gulewitsch and Krimberg 1 discovered this molecule in Liebig's meat extract. From this time, many studies have been carried out on the role of carnitine and acylcarnitine in metabolism. The main studies were addressed to (1) ␤-oxidation of long-chain (and middle-chain) fatty acids in mitochondria; (2) acetyl storage and transfer in mitochondria, cells, and between organs; (3) shuttle of activated middle-and short-chain acids from peroxisomes to mitochondria; (4) Transport of potentially toxic, activated acids out of mitochondria ensuring the availability of free CoA. 2 The role of carnitine in long-chain fatty acids mitochondria metabolism has been known for more than 50 years, and just 25 years ago, the first case of primary carnitine deficiency and its life incompatibility was described. A chronic carnitine deficiency induced an accumulation of fatty acids in tissues and changes in energy metabolism characterized by hypoglycemia, hyperammoniemia, cardiomyopathy, and severe muscle weakness. 3 In humans, carnitine plays a pivotal role in energy metabolism through the transportation of long-chain fatty acids across the inner mitochondrial membrane and controlling the rates of betaoxidations of long-chain fatty acids with subsequent energy production (ATP). 4 The shuttle of long-chain fatty acids into the mitochondria is controlled by at least 3 different proteins: carnitine palmitoyltransferase I (CPT-I), acylcarnitine translocase (CT), and carnitine palmitoyltransferase II(CPT-II); Fig 1. 5 Moreover, carnitine also is involved in glucose mitochondria metabolism. 6 This action is caused by pyruvate dehydrogenase together with carnitine-acyltransferase (CAT), which shuttle acetyl groups of acetylCoA from the mitochondria to carnitine thus inducing acylcarnitine. The result of this action is a decrease in mitochondria levels of acyl-CoA that would otherwise inhibit pyruvate dehydrogenase activity.
It has been shown that carnitine has other roles in the cell correlated to the distribution of the same enzymes (CPT-I, CPT-II, CT, CAT) not only in mitochondria but also in other parts of the cell. 7 Under normal conditions, carnitine distribution in skeletal muscle accounts for more than 90% of total body carnitine, whereas only 1.6% of total body carnitine is contained in the liver and the kidney and 0.6% in extracellular fluids. 8 Brain concentration is relatively low, although it represents one of the few organs with endogen biosynthesis capability. In body fluids, carnitine is present in free and esterified forms (acylcarnitines). Remarkably, the proportion of esterified carnitine may vary considerably with nutritional status, exercise level, and disease state. In humans under normal conditions, acylcarnitines account for about 20% of total carnitine in serum, 10% to 15% in muscle and liver and 50% to 60% in the urine. More than 90% of filtered carnitine (at normal plasma concentrations) is reabsorbed by the proximal renal tubule. 9 Carnitine plasma concentrations result from the combination of intestinal rearbsorbtion, mild endogenous synthesis, and high renal rearbsorbtion. Hemodialysis may promote excessive losses because filters do not allow carnitine reabsorption (Fig 2) . Serum carnitine is considered a problem when it is lower than 20 mol/L.
Plasma concentration of free carnitine is in dynamic balance with that of acylcarnitines, and the acyl to free carnitine ratio is considered normal when it is Յ0.4.
Acyl and free carnitine serum concentrations are, respectively, 12.8 Ϯ 7.4 and 67 Ϯ 21.8 mol/L (acyl to free carnitine ratio Յ0,4) and in cerebrospinal fluid, respectively, 3.5 Ϯ 1.2 e 5.4 Ϯ 2.1 mol/L. 10 In urine, the acyl/free carnitine ratio is modified for almost the total presence of the esterified form.
CARNITINE METABOLISM IN THE UREMIC PATIENT
The disturbance and progressive metabolic dysfunction of the carnitine system owing to the uremic state is not likely to get worse during dialysis treatment. Hemodialysis involves carnitine as one of the solutes capable of crossing the dialyzer membrane through osmosis, which, because of the increase in the age of the patients on dialysis, impairs the metabolic system. Older patients on dialysis present with changes in the serum concentration of carnitine during dialysis treatment that are correlated to a decrease in carnitine contents, thus, leading to a dysfunction of carnitine metabolism and a decreased tolerance of tissues to osmotic stress.
In the absence of dialysis therapy, the uremic patient presents greater serum concentrations of free and total carnitine, reaching values between 84 and 117 mol/L. Long-and short-chain acylcarnitines show an increase that is directly correlated to serum creatinine and therefore to the progression of the uremic state. Carnitine muscular concentrations greater than those observed in the healthy subject and alterations in the lipidic metabolism are included in these situations. 11 Dialysis therapy in uremic patients determines a decrease in both free carnitine and plasmatic acylcarnitines after only 6 months of dialysis treatment. Such concentrations are lower after only one single dialysis treatment. After 6 months of treatment with carnitine given through intravenous injection at the end of the dialysis session, plasma concentrations of free carnitine and acylcarnitines undoubtly are greater than the concentrations observed in healthy subjects. Concentrations above normal can be observed immediately after the dialysis session. 12 Therefore, during dialysis treatment, there is a loss of carnitine, but we can observe that although in the normal subject the acyl to free carnitine ratio is 1:5, in the dialysis patient it is 1:3, both before and after dialysis treatment. In addition to such values, we can observe in the normal subject a loss of carnitine of about 500 mg with an acyl to free carnitine ratio of 1:1 and, in the dialytic patient, a lower loss of carnitine of about 180 mg with an acyl to free carnitine ratio of 1:2 on a weekly basis. 12 The special contribution of the kidney to the carnitine systemic balance is more evident when we observe subjects on a vegeterian diet characterized by very low carnitine content, which is present, on the contrary, in a great number in an omnivorous diet (ie, diet includes meat). It is worth noting that almost the same loss of carnitine can be observed in both vegeterians and uremic patients, compared with carnitine dietary contents, which undoubtely are greater in the dialysis patient. Vegeterians show a normal acyl to free carnitine ratio against low carnitine contents. Quantitative and qualitative alterations in the carnitine present in urine also are noteworthy: lacto-ovovegeterians eliminate about 180 mg of carnitine with an acyl to free carnitine ratio of 5:1, whereas vegeterians eliminate about 100 mg of carnitine with an acyl to free carnitine ratio of 34:1. 13 It is evident that the exclusion of the kidney leads to an alteration in the acyl to free carnitine ratio, but the exclusion of the kidney does not explain the loss of carnitine including problems concerning its synthesis, transport, and enzymes. 14 As far as the synthesis is concerned, the absence of the kidney makes the liver the main source of endogenous carnitine. The hypothesis that the liver synthesis may be inhibited or reduced has not been investigated yet. It is well known that the plasmatic concentration of -Ntrimetyl-lisyne, as a former in the carnitine synthesis, is considerably greater than that in the normal subject, who does not show noteworthy levels. 14 The transportation of carnitine leads to different impairments. The increase in -N-trimetyllisyne inhibits in a competitive way the highaffinity carnitine carrier, Naϩ-dependent, organic cation/carnitine transporter (OCTN 2 ), which is itself transported. In addition, even worsening its function, the same carrier is inhibited by some drugs, ie, cefsoludine, emetin, and cortisone, which are used in the therapy of the dialytic patient. 15 The metabolic effects of decreased transportation of carnitine are exemplified by a gene deletion animal models codifying for OCTN 2 in which hypertriglyceride levels can be observed. 16 As far as the carnitine-dependent enzymes are concerned, it has been observed that the palmitoiltransferase carnitine activity is reduced in the skeletal muscle and in the red cells of the dialysis patient. 17, 18 It is well known that patients on hemodialysis have low plasmatic carnitine concentrations, although they have a diet with a normal carnitine intake and a loss during dialysis lower than the loss of normal subjects through urinary excretion. Patients on hemodialysis treated for more than 12 months with Lcarnitine intravenously have normal plasmatic values of carnitine at the end of a dialysis session. Carnitine washout for 4 months induces a mild reduction of plasmatic values. The reintroduction of L-carnitine for 4-months in the dialysate does not increase plasmatic values. 19 The importance of such variations in plasmatic carnitine values is correlated to changes in the composition of skeletal muscle fibers. Indeed, at the end of this period, reduction of diameter of type I fibers was observed. Type II fibers remained unchanged. For this reason, it has been concluded that carnitine has a specific trophic effect on type I fibers, which are characterized by oxidative metabolism. Change of carnitine supplementation route, through the introduction in the dialysate to prevent the osmotic loss during the dialysis session, did not improve the ability of skeletal muscle to determine a normal intake of carnitine. Skeletal muscle needs intravenous route administration to induce a oxidative functional phenotype.
RECENT STUDIES ON CARNITINE IN UREMIC PATIENTS
Several studies have reported the therapeutic effects of L-carnitine in hemodialysis patients. The main conditions that have had beneficial effects from carnitine supplementation are skeletal and cardiac damage, anemia, hypotension, intradialytic arrhythmia, and dyslipidemia. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Our group showed a reduction of asthenia and cramps after L-carnitine treatment that was correlated with increased levels of the metabolite in blood and muscle (Fig 1) . 21 Brass et al. 22 studied the effects of exercise capacity in patients with end-stage renal disease after carnitine supplementation. In this randomized, placebo-controlled study, patients were assigned to receive carnitine (20 mg/kg) and a placebo intravenously for 24 weeks. They found that patients treated with carnitine showed statistically significant smaller deterioration in VO 2max (P ϭ .009) and improvement of fatigue domain (P ϭ 0.03) using the kidney disease questionnaire (KDQ).
Another study, 23 evaluated the concentration of carnitine and glycogen in the skeletal muscle of patients in hemodialysis, starting from the point that plasmatic carnitine concentrations do not reflect the carnitine tissue content. Comparing the skeletal muscle of normal subjects they observed (1) similar levels of total carnitine with reduced levels of free carnitine; (2) skeletal muscle of total and free carnitine significantly reduced; (3) negative correlation between total and free skeletal muscle carnitine and increased age on dialysis; (4) no correlation between plasmatic and skeletal muscle carnitine concentration; (5) glycogen concentration significantly higher, probably because of the changes in type of muscle fibers observed in uremic patients or lower physical activity.
Matsumoto et al 24 studied the effects of 6 months of treatment with L-carnitine (15 mg/kg intravenously at the end of each dialysis session) on lipid metabolism, free radicals, and red cell count. They showed that L-carnitine treatment induced a significant reduction in plasmatic levels of total and HDL cholesterol (P Ͻ 0.05), significant increase of plasmatic antioxidant ability (P Ͻ 0.001) associated with a reduction of malonyl-aldeide (P Ͻ 0.001) plasmatic concentrations, a significant reduction of intrared cell glutation concentrations (P Ͻ 0.001), and reduced erythropoietin consumption.
In another study, Matsumoto et al 25 evaluated the effects of 3 months of treatment with Lcarnitine (500 mg/d oral) on anemia in a hemodi-alysis patient resistant to erythropoietin treatment. The results showed an increase in Ht levels (P ϭ 0.003) and total ability of iron binding (P ϭ 0.05) together with a significant reduction of ferritin serum levels (P ϭ 0.005).
De los Reyes et al 18 studied the intrared cell carnitine and acylcarnitine variations and CPT activity in uremic patients versus normal subjects. They found the following alterations: higher concentration of free carnitine, lower proportion of long-chain acyl-CoA versus free CoA, reduced activity of CPT and glycerophospholipid acyltransferase, and higher long-chain acyl to free carnitine ratio. They concluded that Lcarnitine treatment induced a positive effect on these parameters through an improvement of acylation and reacylation processes of red cell membrane.
A defect in sodium transport system has been shown in uremic patients, which was improved by L-carnitine supplementation. The average value of sodium efflux of dialysis patients (through the Naϩ/Kϩ oubain-sensitive pump), is significantly reduced, whereas sodium content is higher, and there are no differences in sodium passive permeability. 26 Matsumura et al 27 also showed that the serumfree and total carnitine levels, but not the acylcarnitine, correlate to erythrocyte osmotic fragility evaluated as a point of maximal emolysis, starting emolysis, and average of final emolysis. Moreover, both types of carnitine correlate to erythropoietin dosage. Low serum levels of free carnitine worsen the condition of erythrocyte osmotic fragility and negatively influence the therapeutic efficacy of erythropoietin on anemia.
Nikolaos et al 28 showed that 3 months of treatment with L-carnitine (30 m/kg for dialysis session) significantly reduces the deformability of red blood cells (P Ͻ 0.004) and significantly increases Ht (P Ͻ 0.001). 28 Echocardiographic measurements of cardiac activity have been performed on dialysis patients to study the effect of chronic oral supplementation of L-carnitine; the results showed a statistically significant improvement of systolic and diastolic function of left ventricula. 29 Sakurabayashi et al. 30 performed a myocardial scintigraphy using beta-methyliodophenyl pentadecaonic acid (BMIPP), which showed improved cardiac activity connected to lower time of washout of BMIPP (P Ͻ 0.05). 30 Recently, Hurot et al 31 performed a systematic review to determine the effects of L-carnitine in maintenance hemodialysis patients. They analyzed, from 1978 to 1999, data from 481 patients in 21 trials in which L-carnitine was used and examined changes in serum triglycerides, cholesterol fractions, hemoglobin levels, erythropoietin dose, and other symptoms (muscle function, exercise capacity, and quality of life). In their conclusion, L-carnitine was not recommended for treating the dyslipidemia of maintenance hemodialysis patients, but they suggest the Lcarnitine could be used successfully for treating anemia.
Recently, carnitine supplementation has been approved by the US Food and Drug Administra- tion not only for the treatment, but also for the prevention of carnitine depletion in dialysis patients.
Available studies on carnitine supplementation suggest the use of this molecule in dialysis, especially for those patients with cardiac complications, impaired exercise and functional capacities, lack of energy affecting quality of life, and increased episodes of hypotension. Moreover, in some patients, the improved stability of erythrocyte membranes may decrease erythropoietin requirements, thus, leading to a reduction of dialytic costs.
